Ascorbate/methionine-based CH<sub>4</sub> delivery nanomedicine for tumor-targeted therapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39675143.
- Also identified by DOI 10.1016/j.biomaterials.2024.123002.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Methane (CH<sub>4</sub>) is identified to be an emerging anti-inflammation and anti-cancer molecule with high bio-safety, but the targeted delivery of CH<sub>4</sub> is a thorny challenge. Herein, we propose a CH<sub>4</sub> delivery strategy based on an intratumoral H<sub>2</sub>O<sub>2</sub>-triggered cascade reaction of ascorbic acid (AA)/methionine (Met), and have constructed a new nanomedicine (AMN) for tumor-targeted CH<sub>4</sub> therapy. Encouragingly, AMN realizes the effective tumor-targeted delivery and intratumoral H<sub>2</sub>O<sub>2</sub>-responsive release of CH<sub>4</sub>, and exhibits significant anti-cancer effects and high bio-safety. Mechanistically, we have discovered that intratumoral released CH<sub>4</sub> can not only induce the apoptosis of 4T1 tumor cells by inhibiting their mitochondrial metabolism, but also activate tumor immunotherapy by reprogramming tumor-associated macrophages (TAMs) phenotype (M2 to M1). The combination of the above anti-cancer pathways by virtue of tumor-targeted CH<sub>4</sub> delivery makes contribution to outstanding anti-cancer efficacy of AMN. The proposed CH<sub>4</sub> delivery strategy opens a new window for safe and effective tumor therapy.
Medical subject headings
- Ascorbic Acid
- Methionine
- Nanomedicine
- Methane